Cardiac Biomarkers Market Size & Growth Forecast 2026–2035, By Segments (Type, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Cardiac Biomarkers Market size was assessed at USD 22.9 Billion in 2025 and is poised to grow at a 14.4% CAGR between 2026 and 2035, crossing USD 87.92 Billion by 2035. The industry revenue for 2026 is calculated at USD 25.85 billion.
Get more details on this report
Request Free Sample ReportCardiac Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 45.69% share in 2025, supported by established hospital networks, advanced diagnostic laboratories, and routine use of biomarker testing in acute cardiac care.
- Asia Pacific is forecast to expand at a 16.13% CAGR as healthcare systems strengthen diagnostic capacity, improve hospital infrastructure, and increase adoption of advanced cardiac biomarker testing.
Segment Momentum
- Laboratory Testing remains the leading end-use segment because it supports high testing volumes, standardized workflows, and consistent analytical performance across routine hospital and acute cardiac care settings.
- CK-MB is gaining momentum because clinicians increasingly use it alongside primary biomarkers to provide additional diagnostic insight where multi-marker evaluation supports cardiac injury assessment.
Market Expansion Drivers
- Rising cardiovascular disease burden increasing demand for early and accurate diagnostic biomarker testing.
- Expanding point-of-care cardiac testing improving rapid diagnosis in emergency and outpatient settings.
- Advancements in multi-marker panels and high-sensitivity assays improving precision cardiovascular diagnostics.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top companies in the cardiac biomarkers market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), QuidelOrtho Corporation (United States), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (United States), Randox Laboratories Ltd. (United Kingdom), Beckman Coulter, Inc. (United States), Thermo Fisher Scientific Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As the incidence of heart attacks, heart failure, and related cardiovascular conditions continues to put pressure on emergency departments, cardiology units, and primary care pathways, clinicians are relying more heavily on biomarker testing to distinguish cardiac events quickly from non-cardiac causes of chest pain or dyspnea. This is driving demand for the cardiac biomarkers market because hospitals need diagnostic tools that can support faster triage, reduce uncertainty in acute presentations, and guide treatment decisions earlier in the care pathway. The rising disease burden also increases repeat testing volumes, especially for high-risk and elderly patients who require ongoing evaluation, contributing to market size growth through both acute and routine clinical use.
Expanding point-of-care cardiac testing improving rapid diagnosis in emergency and outpatient settings
The wider use of point-of-care platforms is reshaping testing workflows by moving cardiac biomarker analysis closer to the patient, particularly in emergency rooms, ambulances, urgent care centers, and outpatient clinics where turnaround time directly affects clinical action. In the cardiac biomarkers market, This trend is increasing market penetration by making rapid troponin and related testing more practical in settings that cannot depend on central laboratory timelines. Adoption is being reinforced by the operational value of faster rule-in or rule-out decisions, which helps providers accelerate referrals, shorten observation periods, and manage patient flow more efficiently without delaying critical intervention.
Advancements in multi-marker panels and high-sensitivity assays improving precision cardiovascular diagnostics
Improvements in high-sensitivity assays and multi-marker panels are changing how cardiovascular risk and acute injury are detected, allowing clinicians to identify smaller degrees of myocardial damage and interpret complex cardiac presentations with greater confidence. This is driving market development in the cardiac biomarkers market by shifting purchasing preferences toward more advanced assay formats that offer better clinical discrimination than conventional single-analyte approaches. Multi-marker strategies also support broader use in cases where physicians need to differentiate among acute coronary syndrome, heart failure, and other overlapping conditions, increasing the clinical utility of biomarker testing and influencing laboratory upgrade decisions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cardiovascular disease burden increasing demand for early and accurate diagnostic biomarker testing | 2.60% | High | North America, Europe | High | Near Term |
| Expanding point-of-care cardiac testing improving rapid diagnosis in emergency and outpatient settings | 2.30% | High | North America, Asia Pacific | High | Near Term |
| Advancements in multi-marker panels and high-sensitivity assays improving precision cardiovascular diagnostics | 2.00% | High | Europe, North America | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 45.69% share of the cardiac biomarkers market in 2025, bolstered by well-established hospital and diagnostic laboratory networks, broad access to advanced testing platforms, and routine use of biomarker-based evaluation in acute cardiac care. The region’s leadership is strengthened by high testing volumes for conditions such as myocardial infarction and heart failure, where rapid clinical decision-making depends on reliable biomarker assays integrated into emergency and inpatient workflows. Strong adoption of technologically advanced diagnostics and consistent utilization across major care settings help sustain demand at scale.
Asia Pacific is projected to expand at a 16.13% CAGR over the forecast period, with the cardiac biomarkers market gaining momentum as healthcare systems widen access to diagnostic services and providers increase the use of faster, more sensitive cardiac testing. Growth is being impelled by rising patient volumes, improving hospital infrastructure, and greater incorporation of biomarker testing into frontline cardiovascular assessment, particularly in urban and developing care networks. As laboratories and hospitals continue to strengthen diagnostic capacity, the region is seeing faster adoption patterns in both established and emerging healthcare markets.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Quality EmphasisGermany focuses on high-quality cardiac biomarker testing supported by established laboratory networks and hospital diagnostics. Clinical stakeholders prioritize standardized testing methods that strengthen diagnostic confidence and workflow efficiency.
France 🇫🇷
Clinical Testing OptimizationFrance advances cardiac biomarker utilization through integrated hospital diagnostics and cardiovascular disease management programs. Laboratories focus on improving testing accuracy and turnaround times to strengthen routine clinical practice.
Italy 🇮🇹
Acute Care DiagnosticsItaly prioritizes cardiac biomarkers within emergency medicine and specialized cardiology services. Healthcare providers emphasize dependable diagnostic testing that enables faster assessment of suspected cardiac events and supports appropriate treatment planning.
Japan 🇯🇵
Early Detection PriorityJapan emphasizes cardiac biomarkers for early cardiovascular disease detection within its aging population. Healthcare institutions continue adopting sensitive diagnostic technologies that support timely intervention and effective patient monitoring.
South Korea 🇰🇷
Hospital Diagnostic InnovationSouth Korea expands cardiac biomarker adoption through advanced hospital laboratories and modern diagnostic infrastructure. Providers seek rapid testing platforms that improve emergency department efficiency and support evidence-based cardiovascular care.
United States 🇺🇸
Precision Diagnostic ExpansionThe U.S. cardiac biomarkers market benefits from broad adoption of advanced diagnostic testing across emergency care and cardiology services. Healthcare providers prioritize rapid and accurate biomarker assessments to support timely clinical decision-making and patient management.
Segment Leadership and Growth Trends
Cardiac Biomarkers Market Share (%), Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTroponin held a 37.42% share of the cardiac biomarkers market in 2025, maintaining its lead within the type segment because it remains the most established marker in routine cardiac assessment pathways. Its position is backed by broad clinical familiarity, consistent use in hospital-based diagnostic workflows, and strong integration into standard testing panels for suspected cardiac events. In the cardiac biomarkers market, this entrenched role helps sustain demand for troponin across high-volume emergency and laboratory settings where reliability and established interpretation frameworks are critical.
CK-MB is emerging as the fastest-growing segment in the cardiac biomarkers market as providers seek complementary diagnostic information in situations where broader cardiac injury assessment remains relevant. Its growth momentum is tied to practical use in specific testing environments where clinicians value additional biomarker context alongside primary markers, especially when diagnostic decisions benefit from multi-marker evaluation rather than reliance on a single indicator. Relative to more mature alternatives, CK-MB is gaining traction through this supportive role in evolving cardiac testing strategies.
End Use Segment Analysis: Laboratory Testing (Largest Segment) vs Point of Care Testing (Fastest-Growing Segment)
Laboratory Testing accounted for the largest share of the cardiac biomarkers market in 2025, reflecting its central role in established diagnostic infrastructure and routine hospital operations. The segment continues to lead because laboratories handle high testing volumes, support standardized workflows, and provide the analytical consistency required for cardiac biomarker interpretation in acute care settings. This operational depth keeps Laboratory Testing firmly positioned as the primary end-use setting across the cardiac biomarkers market.
Point of Care Testing is the fastest-growing end-use segment in the cardiac biomarkers market, driven by the need for quicker clinical decision-making closer to the patient. Its momentum comes from practical demand for faster turnaround in emergency departments, ambulatory care settings, and other time-sensitive environments where waiting for central lab processing can delay intervention. Compared with conventional laboratory pathways, Point of Care Testing is gaining ground because it aligns more directly with the growing emphasis on rapid triage and immediate treatment decisions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others | Troponin | CK-MB |
| End Use | Laboratory Testing, Point of Care Testing | Laboratory Testing | Point of Care Testing |
| Application | Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others | Acute Coronary Syndrome | Myocardial Infarction |
Competitive Landscape and Market Positioning
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (United States)
5. QuidelOrtho Corporation (United States)
6. bioMérieux SA (France)
7. Bio-Rad Laboratories Inc. (United States)
8. Randox Laboratories Ltd. (United Kingdom)
9. Beckman Coulter Inc. (United States)
10. Thermo Fisher Scientific Inc. (United States)
The cardiac biomarkers market is advancing through improved diagnostic precision and faster disease detection capabilities. Collaborative research initiatives are enhancing biomarker validation and clinical application. Continuous introduction of advanced diagnostic kits is expanding testing capabilities, while technological integration is strengthening laboratory efficiency in the cardiac biomarkers market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| QuidelOrtho Corp. | Nov-25 | QuidelOrtho received FDA 510(k) clearance for its VITROS hs Troponin I Reagent Pack. This high-sensitivity assay is designed for the quantitative measurement of cardiac troponin I in human plasma to aid in the diagnosis of myocardial infarction. The rollout enables laboratories using VITROS systems to integrate guideline-aligned, high-sensitivity testing into existing workflows to improve diagnostic speed and patient outcomes. |
| Roche | Sep-25 | Roche announced positive results from its TSIX Study Program for the Elecsys Troponin T hs Gen 6 assay. The sixth-generation high-sensitivity test demonstrated high precision in identifying acute myocardial infarction and excluding non-AMI cases. Following its recent CE Mark approval, this assay supports more efficient triage and clinical decision-making in emergency departments by enabling rapid, reliable patient assessment. |
| bioMérieux | Jan-25 | bioMérieux entered an agreement to acquire SpinChip Diagnostics ASA, a developer of a rapid point-of-care immunoassay platform. This acquisition strengthens bioMérieux’s position in the point-of-care market by integrating SpinChip’s benchtop analyzer, which delivers high-sensitivity cardiac troponin I and NT-proBNP results from whole blood within 10 minutes, facilitating faster emergency care and reduced hospital turnaround times. |
| Siemens Healthineers | Oct-24 | The Atellica IM High-Sensitivity Troponin I (TnIH) test received U.S. FDA clearance for a new prognostic claim, allowing it to predict major adverse cardiac events and death up to one year post-presentation. This expansion of clinical utility beyond acute diagnosis enables clinicians to perform better risk stratification and long-term management for patients presenting with signs of acute coronary syndrome. |
| OMRON Healthcare | Jul-25 | OMRON Healthcare collaborated with Tricog to launch KeeboHealth, an AI-enabled remote cardiac care platform in India. The platform integrates connected monitoring technologies to track cardiac health indicators, aiming to improve early detection of cardiovascular risks. This initiative underscores a strategic push toward data-driven, continuous remote patient monitoring to enhance long-term management and reduce the incidence of cardiac events. |
| Adaptyx | Oct-25 | Adaptyx secured USD 14 million in seed funding to advance its wearable platform for continuous multi-analyte molecular monitoring. This development reflects a strategic investment in next-generation diagnostic hardware capable of real-time physiological and biomarker tracking, aiming to transition cardiac monitoring from episodic clinical testing to continuous, wearable-enabled remote patient observation. |
| Heart Foundation | May-25 | The Heart Foundation introduced a home heart health kit as part of its “Heart First” initiative. The solution integrates a wearable ECG patch, saliva biosensor, and wireless ultrasound to facilitate comprehensive at-home cardiac monitoring. By enabling multi-modal biomarker and physiological signal tracking, the project aims to increase the accessibility of early detection for heart-related conditions outside of traditional clinical settings. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Cardiac Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Cardiac Biomarkers Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the cardiac biomarkers market?
How much is the cardiac biomarkers industry expected to grow by 2035?
How is rising cardiovascular disease burden impacting demand for cardiac biomarker testing?
How is point-of-care testing reshaping cardiac biomarker diagnostics in clinical workflows?
Why does Laboratory Testing lead the cardiac biomarkers market?
Why is CK-MB the fastest-growing biomarker segment in the cardiac biomarkers market?
What factors make North America the leading cardiac biomarkers market?
Why is Asia Pacific experiencing the fastest growth in the cardiac biomarkers market?
Who are the leading players in the cardiac biomarkers landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization